Bolt Biotherapeutics (BOLT) Cash & Equivalents (2020 - 2026)

Bolt Biotherapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $11.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 38.35% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 38.35% YoY) and the FY2025 annual result came in at $11.7 million, up 62.43% from the prior year.
• Cash & Equivalents slipped to $11.6 million in Q1 2026 per BOLT's latest filing, from $11.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $44.0 million in Q1 2022 and troughed at $4.3 million in Q1 2024.
• A 5-year average of $14.2 million and a median of $10.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 71.27% in 2024, then soared 314.26% in 2025.
• Over 5 years, Cash & Equivalents stood at $9.2 million in 2022, then rose by 16.94% to $10.8 million in 2023, then tumbled by 33.35% to $7.2 million in 2024, then surged by 62.43% to $11.7 million in 2025, then decreased by 0.8% to $11.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $11.6 million, $11.7 million, and $38.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.